Literature DB >> 23187946

Hormonal contraceptive continuation and switching in South Africa: implications for evaluating the association of injectable hormonal contraceptive use and HIV.

Jennifer A Smit1, Mags E Beksinska.   

Abstract

Investigating the association between hormonal contraception and HIV is challenging due to high discontinuation rates among users. This secondary analysis of 262 South African adolescent new users of hormonal contraception found continuation rates after 1 year for depot medroxyprogesterone acetate, norethisterone enanthate, or combined oral contraceptives of 40.4%, 64.4%, and 64.6%, respectively. Implications for studies evaluating the association between injectable hormonal contraceptive use and HIV are discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23187946     DOI: 10.1097/QAI.0b013e31827e818a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial.

Authors:  Margaret R Caplan; Raphael J Landovitz; Thesla Palanee-Phillips; Gonasagrie Nair; Felix Mhlanga; Jennifer E Balkus; Sharon A Riddler; Pamina M Gorbach
Journal:  AIDS Care       Date:  2019-02-13

2.  PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.

Authors:  Connie L Celum; Elizabeth A Bukusi; Linda Gail Bekker; Sinead Delany-Moretlwe; Lara Kidoguchi; Victor Omollo; Elzette Rousseau; Danielle Travill; Jennifer F Morton; Felix Mogaka; Gabrielle O'Malley; Gena Barnabee; Ariane van der Straten; Deborah Donnell; Urvi M Parikh; Lauren Kudrick; Peter L Anderson; Jessica E Haberer; Linxuan Wu; Renee Heffron; Rachel Johnson; Susan Morrison; Jared M Baeten
Journal:  J Int AIDS Soc       Date:  2022-07       Impact factor: 6.707

3.  Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate.

Authors:  Lisa B Haddad; Carrie Cwiak; Denise J Jamieson; Caryl Feldacker; Hannock Tweya; Mina Hosseinipour; Irving Hoffman; Amy G Bryant; Gretchen S Stuart; Isaac Noah; Linly Mulundila; Bernadette Samala; Patrick Mayne; Sam Phiri
Journal:  Contraception       Date:  2013-08-23       Impact factor: 3.375

4.  Contraceptive discontinuation and switching among couples receiving integrated HIV and family planning services in Lusaka, Zambia.

Authors:  Lisa Haddad; Kristin M Wall; Bellington Vwalika; Naw Htee Khu; Ilene Brill; William Kilembe; Rob Stephenson; Elwyn Chomba; Cheswa Vwalika; Amanda Tichacek; Susan Allen
Journal:  AIDS       Date:  2013-10       Impact factor: 4.177

Review 5.  Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches.

Authors:  Chelsea B Polis; Daniel Westreich; Jennifer E Balkus; Renee Heffron
Journal:  AIDS       Date:  2013-10       Impact factor: 4.177

6.  The injectable-only contraceptive medroxyprogesterone acetate, unlike norethisterone acetate and progesterone, regulates inflammatory genes in endocervical cells via the glucocorticoid receptor.

Authors:  Yashini Govender; Chanel Avenant; Nicolette J D Verhoog; Roslyn M Ray; Nicholas J Grantham; Donita Africander; Janet P Hapgood
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

7.  Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.

Authors:  Rochelle P Walensky; Margo M Jacobsen; Linda-Gail Bekker; Robert A Parker; Robin Wood; Stephen C Resch; N Kaye Horstman; Kenneth A Freedberg; A David Paltiel
Journal:  J Infect Dis       Date:  2015-12-17       Impact factor: 5.226

8.  WHISPER or SHOUT study: protocol of a cluster-randomised controlled trial assessing mHealth sexual reproductive health and nutrition interventions among female sex workers in Mombasa, Kenya.

Authors:  Frances H Ampt; Collins Mudogo; Peter Gichangi; Megan S C Lim; Griffins Manguro; Matthew Chersich; Walter Jaoko; Marleen Temmerman; Marilyn Laini; Liz Comrie-Thomson; Mark Stoové; Paul A Agius; Margaret Hellard; Kelly L'Engle; Stanley Luchters
Journal:  BMJ Open       Date:  2017-08-18       Impact factor: 2.692

9.  Global implementation of PrEP for HIV prevention: setting expectations for impact.

Authors:  Maria N Pyra; Jessica E Haberer; Nina Hasen; Jason Reed; Nelly R Mugo; Jared M Baeten
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

10.  Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.

Authors:  Connie L Celum; Katherine Gill; Jennifer F Morton; Gabrielle Stein; Laura Myers; Katherine K Thomas; Margaret McConnell; Ariane van der Straten; Jared M Baeten; Menna Duyver; Eve Mendel; Keshani Naidoo; Jacqui Dallimore; Lubbe Wiesner; Linda-Gail Bekker
Journal:  J Int AIDS Soc       Date:  2020-11       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.